COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Total Liabilities
Everything the company owes to creditors and other parties.
COMPASS Pathways plcNASDAQ: CMPS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 65.8% from a year ago
Total liabilities stood at $205.05M at the end of Q1 FY2026, up 65.8% from a year earlier and down 22.1% from the prior quarter. Over 3 fiscal years it compounded at +154.2% a year.
Context
- Total liabilities amounted to 38.6% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +65.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 263.2M USD
- Year-over-year change
- +346.3%
- 4-year CAGR
- +99.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 263.2M | +346.3% |
| FY2024 | 2024-12-31 | 58.97M | +17.4% |
| FY2023 | 2023-12-31 | 50.24M | +213.7% |
| FY2022 | 2022-12-31 | 16.01M | -2.9% |
| FY2021 | 2021-12-31 | 16.49M | — |
Total Liabilities vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's Mar 2026 total liabilities of $205.05M is the 5th highest of the 11 companies compared; the peer median is $79.37M.
- Its year-over-year change of +65.8% is the 4th highest of 11, against a peer median of +13.9%.
- Total liabilities amounts to 38.6% of total assets for CMPS, versus a peer median of 7.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $296.65B | +474318.1% | +47.0% | 312.0% | |
| Sep 2026 | $406.66M | -1.7% | +21.6% | 22.7% | |
| Jun 2026 | $373.84M | +11.6% | +14.0% | 27.2% | |
| Jun 2026 | $322.78M | +131.9% | -32.0% | 27.9% | |
| Mar 2026 | $205.05M | +65.8% | +154.2% | 38.6% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $106.25M | -0.1% | +78.1% | 9.9% |
| Sep 2026 | $52.5M | -0.7% | +15.3% | 4.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $26.09M | +60.8% | +31.9% | 5.2% |
| Mar 2026 | $18.95M | +2.1% | +4.5% | 4.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $14.79M | +66.9% | -38.6% | 3.8% |
| Mar 2026 | $11.89M | +16.1% | +23.3% | 4.3% | |
| Peer median (excluding CMPS) | $79.37M | +13.9% | +18.4% | 7.6% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 273.24M | 143.21M | 220.2M | 165.08M | 149.61M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 11.22M | 15.62M | 28.93M | 21.82M | 15.39M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.31M | 1.22M | 2.34M | 2.58M | 5.96M |
| Total Current Assets | 295.3M | 191.65M | 261.3M | 201.29M | 191.49M |
| Property, Plant & Equipment (Net) | 4.09M | 2.62M | 4.73M | 2.2M | 3.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 525K | 469K | 469K | 469K | 10.95M |
| Tax Assets | 766K | 2.22M | 3.34M | 3.77M | 3.75M |
| Other Non-current Assets | 213K | 327K | 6.16M | 5.94M | 734K |
| Total Non-current Assets | 5.6M | 5.64M | 14.69M | 12.38M | 18.86M |
| Total Assets | 300.9M | 197.29M | 275.99M | 213.67M | 210.35M |
| Account Payables | 2.56M | 4.76M | 5.89M | 12.28M | 15.22M |
| Short-term Debt | 0 | 0 | 0 | 5.51M | 19.63M |
| Tax Payables | 593K | 167K | 13K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.29M | 6.19M | 8.09M | 9.24M | 212.94M |
| Total Current Liabilities | 15.11M | 15.6M | 19.6M | 34.02M | 247.8M |
| Long-term Debt | 0 | 0 | 28.76M | 24.65M | 1.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 14.11M |
| Total Non-current Liabilities | 1.38M | 418K | 30.64M | 24.96M | 15.4M |
| Total Liabilities | 16.49M | 16.01M | 50.24M | 58.97M | 263.2M |
| Common Stock | 435K | 440K | 635K | 702K | 973K |
| Retained Earnings | (169.64M) | (261.15M) | (379.61M) | (534.73M) | (822.59M) |
| Accumulated OCI | 8.84M | (16.87M) | (16.93M) | (16.19M) | (14.79M) |
| Other Stockholders Equity | 28K | 28K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 284.41M | 181.28M | 225.74M | 154.7M | (52.85M) |
| Total Debt | 3.61M | 1.93M | 33.05M | 32.19M | 20.93M |
| Net Debt | (269.63M) | (141.28M) | (187.15M) | (132.89M) | (128.68M) |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.